KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Total Current Liabilities (2017 - 2025)

Historic Total Current Liabilities for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $862.1 million.

  • Amneal Pharmaceuticals' Total Current Liabilities fell 2128.39% to $862.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $862.1 million, marking a year-over-year decrease of 2128.39%. This contributed to the annual value of $1.1 billion for FY2024, which is 3344.88% up from last year.
  • According to the latest figures from Q3 2025, Amneal Pharmaceuticals' Total Current Liabilities is $862.1 million, which was down 2128.39% from $1.1 billion recorded in Q2 2025.
  • Amneal Pharmaceuticals' Total Current Liabilities' 5-year high stood at $1.1 billion during Q4 2024, with a 5-year trough of $602.0 million in Q1 2022.
  • In the last 5 years, Amneal Pharmaceuticals' Total Current Liabilities had a median value of $818.0 million in 2022 and averaged $848.8 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first tumbled by 3401.7% in 2021, then soared by 4758.81% in 2022.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Total Current Liabilities stood at $677.2 million in 2021, then increased by 11.16% to $752.8 million in 2022, then rose by 12.46% to $846.6 million in 2023, then skyrocketed by 33.45% to $1.1 billion in 2024, then decreased by 23.69% to $862.1 million in 2025.
  • Its last three reported values are $862.1 million in Q3 2025, $1.1 billion for Q2 2025, and $1.1 billion during Q1 2025.